Wall Street analysts expect Iqvia Holdings Inc (NYSE:IQV) to post $2.84 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Iqvia’s earnings. The highest sales estimate is $2.86 billion and the lowest is $2.83 billion. Iqvia posted sales of $2.69 billion during the same quarter last year, which suggests a positive year over year growth rate of 5.6%. The company is expected to announce its next quarterly earnings results on Thursday, February 13th.

According to Zacks, analysts expect that Iqvia will report full year sales of $11.04 billion for the current financial year, with estimates ranging from $11.02 billion to $11.08 billion. For the next financial year, analysts forecast that the firm will report sales of $11.84 billion, with estimates ranging from $11.76 billion to $11.88 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Iqvia.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, October 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.03. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.76 billion. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.42 earnings per share.

A number of analysts have recently issued reports on IQV shares. Wells Fargo & Co increased their target price on Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Wolfe Research upgraded Iqvia from a “peer perform” rating to an “outperform” rating in a report on Thursday, November 14th. Credit Suisse Group increased their target price on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. JPMorgan Chase & Co. increased their target price on Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Finally, ValuEngine lowered Iqvia from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Three research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $166.46.

Shares of IQV traded up $1.12 during mid-day trading on Monday, reaching $143.48. The company’s stock had a trading volume of 1,000,775 shares, compared to its average volume of 1,288,906. The business has a fifty day moving average of $144.76 and a 200 day moving average of $148.62. The company has a market cap of $28.43 billion, a price-to-earnings ratio of 28.02, a price-to-earnings-growth ratio of 1.62 and a beta of 0.87. Iqvia has a 1 year low of $104.90 and a 1 year high of $164.13. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 1.85.

Several hedge funds and other institutional investors have recently bought and sold shares of IQV. Foundations Investment Advisors LLC increased its stake in shares of Iqvia by 23.6% in the second quarter. Foundations Investment Advisors LLC now owns 6,630 shares of the medical research company’s stock worth $1,070,000 after acquiring an additional 1,266 shares during the last quarter. WINTON GROUP Ltd increased its position in Iqvia by 5.2% during the second quarter. WINTON GROUP Ltd now owns 8,869 shares of the medical research company’s stock worth $1,427,000 after buying an additional 435 shares during the last quarter. Chesley Taft & Associates LLC increased its position in Iqvia by 6.6% during the second quarter. Chesley Taft & Associates LLC now owns 6,055 shares of the medical research company’s stock worth $974,000 after buying an additional 375 shares during the last quarter. Zweig DiMenna Associates LLC acquired a new position in Iqvia during the second quarter worth $20,207,000. Finally, Valeo Financial Advisors LLC increased its position in Iqvia by 23.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,050 shares of the medical research company’s stock worth $330,000 after buying an additional 387 shares during the last quarter. 91.39% of the stock is currently owned by institutional investors and hedge funds.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: 52-Week High/Low

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.